Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2007

Glycominds and Fox Chase Cancer Center Partner to Discover Breast Cancer Diagnostic Blood Test

  • Glycominds entered into a research agreement with Fox Chase Cancer Center (FCCC) to develop a new blood test for breast cancer.

    “Glycominds’ antiglycan antibodies biomarkers approach together with FCCC’s excellent patient records, samples, and clinical know-how give this project a high basis for success,” asserts Nir Dotan, Ph.D., Glycominds’ cofounder, CTO, and vp of R&D.

    “I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer,” notes Andrew K. Godwin, Ph.D., director of the clinical molecular genetics laboratory and the biosample repository at FCCC.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »